



AuroMedics Pharma is voluntarily recalling two lots of Piperacillin and Tazobactam for Injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP” FDA (2018).

FDA report “AuroMedics Pharma is voluntarily recalling two lots of Piperacillin and Tazobactam for Injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level.

---

### You may also be interested in...

- Assessment of use of infection prevention techniques and technologies
- Infusion of piperacillin/tazobactam and meropenem in critically ill patients
- Y-site compatibility testing between vancomycin and piperacillin-tazobactam

---

The products have been found to contain particulate matter, visible only after reconstitution



AuroMedics Pharma is recalling two lots of piperacillin and tazobactam for injection | 2

that was confirmed to be glass within the vial. The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening.

To date, AuroMedics Pharma has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed from these lots.”

[Full Text](#)

